EFTR Insider Trading

Insider Ownership Percentage: 8.40%
Insider Buying (Last 12 Months): $197.22
Insider Selling (Last 12 Months): $0.00

eFFECTOR Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at eFFECTOR Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

eFFECTOR Therapeutics Share Price & Price History

Current Price: $0.60
Price Change: Price Increase of +0.03 (5.26%)
As of 09/29/2023 01:00 AM ET

This chart shows the closing price history over time for EFTR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

eFFECTOR Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/4/2022Christopher B. EhrlichDirectorBuy346$0.57$197.2235,213View SEC Filing Icon  
9/26/2022Christopher B. EhrlichDirectorBuy18,867$0.55$10,376.8534,867View SEC Filing Icon  
8/3/2022Presidio Management Group X LlMajor ShareholderSell59,376$0.80$47,500.80127,569View SEC Filing Icon  
8/1/2022Presidio Management Group X LlMajor ShareholderSell26,703$0.79$21,095.37130,218View SEC Filing Icon  
7/27/2022Presidio Management Group X LlMajor ShareholderSell43,665$0.89$38,861.85132,009View SEC Filing Icon  
7/25/2022Presidio Management Group X LlMajor ShareholderSell2,279$0.93$2,119.47133,414View SEC Filing Icon  
7/22/2022Presidio Management Group X LlMajor ShareholderSell7,614$0.91$6,928.74133,483View SEC Filing Icon  
7/20/2022Presidio Management Group X LlMajor ShareholderSell10,030$1.00$10,030.00133,795View SEC Filing Icon  
7/18/2022Presidio Management Group X LlMajor ShareholderSell20,987$1.08$22,665.96134,183View SEC Filing Icon  
7/15/2022Presidio Management Group X LlMajor ShareholderSell45,900$1.11$50,949.00134,818View SEC Filing Icon  
6/23/2022Brian M Jr. GallagherDirectorBuy30,000$1.59$47,700.0030,000View SEC Filing Icon  
6/7/2022Michael ByrnesCFOBuy25,000$1.33$33,250.0029,233View SEC Filing Icon  
6/7/2022Stephen T WorlandInsiderBuy20,000$1.37$27,400.00214,978View SEC Filing Icon  
5/18/2022Presidio Management Group X LlMajor ShareholderSell14,086$1.73$24,368.78136,507View SEC Filing Icon  
5/16/2022Presidio Management Group X LlMajor ShareholderSell12,769$1.75$22,345.75137,309View SEC Filing Icon  
5/13/2022Presidio Management Group X LlMajor ShareholderSell22,607$1.84$41,596.88137,704View SEC Filing Icon  
5/11/2022Presidio Management Group X LlMajor ShareholderSell5,000$2.35$11,750.00138,741View SEC Filing Icon  
5/9/2022Presidio Management Group X LlMajor ShareholderSell4,000$2.54$10,160.00140,137View SEC Filing Icon  
2/18/2022Christopher B. EhrlichDirectorBuy1,000$4.30$4,300.00View SEC Filing Icon  
2/14/2022Christopher B. EhrlichDirectorBuy2,000$4.45$8,900.00View SEC Filing Icon  
2/8/2022Christopher B. EhrlichDirectorBuy1,000$4.92$4,920.00View SEC Filing Icon  
2/3/2022Christopher B. EhrlichDirectorBuy5,000$5.15$25,750.00View SEC Filing Icon  
1/27/2022Christopher B. EhrlichDirectorBuy5,000$5.30$26,500.00View SEC Filing Icon  
12/2/2021Jonathan D. RootDirectorSell8,113$5.68$46,081.84View SEC Filing Icon  
12/1/2021Presidio Management Group X LlMajor ShareholderSell19,245$6.44$123,937.80View SEC Filing Icon  
11/30/2021Jonathan D. RootDirectorSell27,409$6.53$178,980.77View SEC Filing Icon  
11/29/2021Presidio Management Group X LlMajor ShareholderSell25,764$6.70$172,618.80View SEC Filing Icon  
11/26/2021Jonathan D. RootDirectorSell5,026$7.01$35,232.26View SEC Filing Icon  
11/24/2021Jonathan D. RootDirectorSell36,520$7.36$268,787.20View SEC Filing Icon  
11/23/2021Presidio Management Group X LlMajor ShareholderSell14,879$7.40$110,104.60View SEC Filing Icon  
11/22/2021Jonathan D. RootDirectorSell26,183$7.86$205,798.38View SEC Filing Icon  
11/19/2021Jonathan D. RootDirectorSell7,241$8.12$58,796.92View SEC Filing Icon  
11/18/2021Presidio Management Group X LlMajor ShareholderSell16,745$8.53$142,834.85View SEC Filing Icon  
11/17/2021Jonathan D. RootDirectorSell10,235$9.13$93,445.55View SEC Filing Icon  
11/16/2021Presidio Management Group X LlMajor ShareholderSell8,319$9.42$78,364.98View SEC Filing Icon  
11/15/2021Jonathan D. RootDirectorSell5,071$9.81$49,746.51View SEC Filing Icon  
11/12/2021Presidio Management Group X LlMajor ShareholderSell12,000$10.07$120,840.00View SEC Filing Icon  
11/11/2021Jonathan D. RootDirectorSell12,017$10.37$124,616.29View SEC Filing Icon  
11/10/2021Presidio Management Group X LlMajor ShareholderSell34,000$10.44$354,960.00View SEC Filing Icon  
11/9/2021Jonathan D. RootDirectorSell28,785$11.00$316,635.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for eFFECTOR Therapeutics (NASDAQ:EFTR)

57.67% of eFFECTOR Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at EFTR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

eFFECTOR Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/11/2023Renaissance Technologies LLC880,908$0.73M0.0%+512.2%2.078%Search for SEC Filing on Google Icon
6/5/2023EP Wealth Advisors LLC17,607$1.65M0.0%N/A0.042%Search for SEC Filing on Google Icon
5/16/2023Sea Otter Advisors LLC263,942$93K0.0%N/A0.622%Search for SEC Filing on Google Icon
5/12/2023Renaissance Technologies LLC143,900$51K0.0%-34.6%0.339%Search for SEC Filing on Google Icon
5/5/2023Carlyle Group Inc.4,822,114$1.69M0.1%N/A11.373%Search for SEC Filing on Google Icon
2/15/2023CI Private Wealth LLC275,442$0.12M0.0%N/A0.658%Search for SEC Filing on Google Icon
2/13/2023Renaissance Technologies LLC219,900$94K0.0%+12.5%0.525%Search for SEC Filing on Google Icon
11/15/2022Two Sigma Investments LP47,223$27K0.0%N/A0.113%Search for SEC Filing on Google Icon
11/15/2022Vanguard Group Inc.429,043$0.25M0.0%-17.0%1.024%Search for SEC Filing on Google Icon
11/14/2022Renaissance Technologies LLC195,399$0.11M0.0%+567.2%0.466%Search for SEC Filing on Google Icon
8/16/2022Callan Capital LLC20,000$28K0.0%N/A0.048%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC29,288$42K0.0%N/A0.071%Search for SEC Filing on Google Icon
8/2/2022Resolute Financial LLC30,000$43K0.0%N/A0.072%Search for SEC Filing on Google Icon
8/1/2022Parallel Advisors LLC1,693,559$2.41M0.1%+150.0%4.092%Search for SEC Filing on Google Icon
5/16/2022State Street Corp17,000$68K0.0%N/A0.041%Search for SEC Filing on Google Icon
4/28/2022Parallel Advisors LLC677,452$2.74M0.1%N/A1.637%Search for SEC Filing on Google Icon
2/15/2022SR One Capital Management LP6,822,114$56.49M31.9%N/A16.898%Search for SEC Filing on Google Icon
2/9/2022Alps Advisors Inc.51,942$0.43M0.0%N/A0.129%Search for SEC Filing on Google Icon
2/3/2022OUP Management Co. LLC1,025,697$8.49M3.8%N/A2.541%Search for SEC Filing on Google Icon
11/16/2021Verition Fund Management LLC24,667$0.35M0.0%N/A0.061%Search for SEC Filing on Google Icon
11/15/2021Abingworth LLP4,822,114$67.03M15.2%N/A11.964%Search for SEC Filing on Google Icon
11/15/2021Sectoral Asset Management Inc2,882,744$40.50M3.4%N/A7.153%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
eFFECTOR Therapeutics logo
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Read More on eFFECTOR Therapeutics

Today's Range

Now: $0.60
Low: $0.58
High: $0.62

50 Day Range

MA: $0.67
Low: $0.49
High: $0.81

52 Week Range

Now: $0.60
Low: $0.34
High: $1.48


896,701 shs

Average Volume

366,403 shs

Market Capitalization

$25.44 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of eFFECTOR Therapeutics?

eFFECTOR Therapeutics' top insider investors include:
  1. Stephen T Worland (Insider)
  2. Presidio Management Group X Ll (Major Shareholder)
  3. Christopher B Ehrlich (Director)
  4. Brian M Jr Gallagher (Director)
  5. Michael Byrnes (CFO)
  6. Jonathan D Root (Director)
Learn More about top insider investors at eFFECTOR Therapeutics.